Сравнение
Leuprorelin vs. Terlipressin
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
53714-56-0
14636-12-5
Молекулярная масса
1209.4 g/mol
1227.37 g/mol
Период полувыведения
3 h
нет данных
Последовательность
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtнет данных
Механизм действия
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Terlipressin
Terlipressin is slowly converted in the body to lysine-vasopressin by cleavage of the three N-terminal glycyl residues (reservoir effect) and activates V1 receptors. The splanchnic vasoconstriction improves renal perfusion in hepatorenal syndrome.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
1
из них на людях
4
1
Зафиксированные эффекты
4
2
Открытые противоречия
1
0
Задокументированные нежелательные явления
3
1
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Leuprorelin and Terlipressin?
- Leuprorelin is classified as "Исследования (прочее)", while Terlipressin is classified as "Исследования (прочее)". Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Leuprorelin or Terlipressin?
- The highest available evidence level is "РКИ на людях" for Leuprorelin and "РКИ на людях" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Leuprorelin and Terlipressin in Germany and the United States?
- Германия: Leuprorelin — Рецептурный, Terlipressin — Рецептурный. США: Leuprorelin — Рецептурный, Terlipressin — Рецептурный. These are factual summaries with source and review date on the individual pages.